Category: Bayer AG

Time to act in CKD: Finerenone as a pillar of treatment in T2D patients

Bayer AG |
Thursday

Chair: Lori Berard (CAN) 15:00 – 15:05 Welcome and introduction Lori Berard (CAN) 15:05 – 15:25 Round table Time to act in CKD: Finerenone as

Legal notice | Data protection

Manage Cookie Consent

We use cookies to optimize our website and service.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Vorlieben Vorlieben

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Show settings

{title} {title} {title}

Category: Bayer AG

Time to act in CKD: Finerenone as a pillar of treatment in T2D patients Bayer AG | Thursday

Time to act in CKD: Finerenone as a pillar of treatment in T2D patients

Bayer AG |
Thursday